Based on Russian customs filings and bank records, this investigation marks the first time a supply route for American technology has been traced all the way to a Russian manufacturer, whose weapon system is used in Ukraine.
- MarketsWall Street slumps as Fed heightens recession fears
U.S. stock indexes closed sharply lower on Thursday, with each of the major averages suffering their biggest daily percentage drop in weeks, as fears intensified that the Federal Reserve's battle against inflation using aggressive interest rate hikes could lead to a recession.
- WorldPuerto Rico independence vote bill passes U.S. House
It is a boost for Puerto Rico's movement for greater self-government.
- WorldLandslide near Malaysian capital kills two, dozens missing -officials
Two people are dead and more than 50 are missing after a landslide struck a campsite in Malaysia early on Friday, officials said, as search and rescue personnel scoured the site for survivors.
A Reuters Investigation
Nightmare in NigeriaSecrets behind the Nigerian military's campaign to crush the nation's Islamist insurgency: a mass abortion program and targeted killings of children
- Electric vehicles confront the leap to the mass marketCharged ·
December 16, 2022 · 12:02 AM UTC The past year was sobering for investors who poured money into Tesla Inc and rival electric vehicle startups that hoped to emulate Tesla CEO Elon Musk's success.
Graphic
How China's dams starve the Mekong River Delta of vital sediment
Talking Points
- Healthcare & PharmaceuticalsGuardant DNA blood test finds 83% of colorectal cancers in trial, shares fall 39%
Guardant Health Inc on Thursday said a pivotal trial of its DNA blood test showed that it detected 83% of colorectal cancers and 13% of advanced adenomas, a cancer precursor, but the results fell short of a rival stool-based test, sending the company's shares sharply lower.
- WorldU.S. Parkinson's disease incidence far higher than earlier estimates, study shows
The annual number of new Parkinson's disease diagnoses is likely 50% higher than estimated, based on a broad analysis of insurance claims and population growth.